Modern antithrombotic treatment in patients with atherosclerotic cardiovascular diseases. The position of rivaroxaban in current guidelines and everyday clinical practice Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
rivaroxaban, antithrombotic treatment, atherosclerotic cardiovascular diseases
Main Article Content
Abstract
Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease, cerebrovascular disease, and peripheral arterial disease, is associated with high morbidity, mortality, and cost on a population scale. Antiplatelet monotherapy has been the basis of antithrombotic therapy for the primary and secondary prevention of ASCVD events. Recent randomized trials have demonstrated the benefits and effectiveness of dual pathway inhibition (DPI) strategy in chronic ASCVD. Acetylsalicylic acid used in combination with a low dose of rivaroxaban has a synergistic effect and is an attractive therapeutic option in selected groups of patients.
Article Details
How to Cite
Stępień, K., & Gajos, G. (2024). Modern antithrombotic treatment in patients with atherosclerotic cardiovascular diseases. The position of rivaroxaban in current guidelines and everyday clinical practice. Medycyna Faktow (J EBM), 17(1(62), 43-50. https://doi.org/10.24292/01.MF.0124.07
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76: 2982-3021.
2. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9.
3. Stepien K, Nowak K, Skorek P et al. Baseline indicators of coronary artery disease burden in patients with non-ST-segment elevation acute coronary syndrome. Minerva Cardioangiol. 2019; 67: 181-90.
4. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual\ participant data from randomised trials. Lancet. 2009; 373: 1849-60.
5. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44: 3720-826.
6. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52: e364-467.
7. Gerhard-Herman MD, Gornik HL, Barrett C et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e686-725.
8. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-17.
9. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.
10. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37: 390-9.
11. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309-20.
12. Diener HC, Bogousslavsky J, Brass L et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
13. Zalewski J, Stepien K, Nowak K et al. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. J Clin Med. 2020; 9: 2018.
14. Andreotti F, Testa L, Biondi-Zoccai GGL et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006; 27: 519-26.
15. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-27.
16. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.
17. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
18. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
19. Eikelboom J, Connolly S, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
20. Bonaca MP, Bauersachs RM, Hiatt WR et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.
2. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9.
3. Stepien K, Nowak K, Skorek P et al. Baseline indicators of coronary artery disease burden in patients with non-ST-segment elevation acute coronary syndrome. Minerva Cardioangiol. 2019; 67: 181-90.
4. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual\ participant data from randomised trials. Lancet. 2009; 373: 1849-60.
5. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44: 3720-826.
6. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52: e364-467.
7. Gerhard-Herman MD, Gornik HL, Barrett C et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e686-725.
8. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-17.
9. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.
10. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37: 390-9.
11. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309-20.
12. Diener HC, Bogousslavsky J, Brass L et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364: 331-7.
13. Zalewski J, Stepien K, Nowak K et al. Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. J Clin Med. 2020; 9: 2018.
14. Andreotti F, Testa L, Biondi-Zoccai GGL et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006; 27: 519-26.
15. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-27.
16. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.
17. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374: 29-38.
18. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
19. Eikelboom J, Connolly S, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.
20. Bonaca MP, Bauersachs RM, Hiatt WR et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.